Pancreatic Cancer Treatment in Hyderabad — Expert Oncology Care Across 7 Locations

Pancreatic Cancer in Hyderabad — What You Need to Know

The pancreas is a dual-function organ — it produces digestive enzymes that break down food, and hormones including insulin that regulate blood sugar. Pancreatic cancer develops when cells in this organ begin to grow uncontrollably — and for a plain-language overview you can watch a Mayo Clinic specialist explain pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) — originating in the cells lining the pancreatic ducts — accounts for approximately 93% of all pancreatic cancers. Pancreatic neuroendocrine tumours (PNETs), arising from the hormone-producing cells, comprise the remaining 7% and carry a significantly different, generally more favourable prognosis.

The primary challenge with pancreatic cancer is late presentation — approximately 80% of patients are diagnosed at Stage III or Stage IV, when the cancer has either involved major blood vessels or spread to distant organs. However, even in advanced stages, carefully managed chemotherapy, radiation, and supportive care can meaningfully extend life and preserve quality of life. For the roughly 20% of patients diagnosed at an earlier stage, surgery offers a genuine chance of cure.

Hyderabad's rising rates of type 2 diabetes, obesity, and chronic pancreatitis — all significant risk factors for PDAC — make early awareness and specialist access increasingly important across the city.

Types of Pancreatic Cancer We Treat

Pancreatic cancer is not one disease. The histological type — adenocarcinoma versus neuroendocrine versus rare subtypes — determines prognosis, treatment, and the specialists you need. CION's tumour board confirms the exact type for every patient before any treatment decision.

Risk Factors for Pancreatic Cancer

Several factors increase the risk of developing pancreatic cancer. Many are modifiable; others — like family history and inherited gene mutations — guide screening decisions. Discuss your personal risk profile with a CION specialist if more than one applies to you.

• Smoking — doubles the risk of PDAC; one of the most modifiable risk factors
• Chronic pancreatitis — long-standing pancreatic inflammation significantly raises PDAC risk
• Type 2 diabetes — particularly new-onset diabetes in older adults without traditional risk factors
• Obesity — especially central/abdominal obesity, increasingly prevalent in urban Hyderabad
• Family history of pancreatic cancer — first-degree relatives carry 2–3 times higher risk
• Hereditary gene mutations — BRCA1/BRCA2, PALB2, ATM, CDKN2A, MLH1/MSH2 (Lynch syndrome); account for approximately 10% of PDAC cases
• Long-standing chronic pancreatitis from any cause (gallstones, alcohol, autoimmune)
• Age above 60 — most cases occur in the sixth to eighth decade

Symptoms of Pancreatic Cancer

Pancreatic cancer is frequently called a 'silent disease' — symptoms are often absent or non-specific in early stages, which is why most cases are diagnosed late. The following symptoms warrant urgent specialist evaluation:

• Painless jaundice — yellow skin and eyes, dark urine, pale stools; caused by bile duct obstruction from a tumour in the head of the pancreas; the most actionable early warning sign
• Upper abdominal pain radiating to the mid-back — often worse when lying down, improves leaning forward
• Unexplained significant weight loss and loss of appetite
• New-onset diabetes or sudden worsening of previously well-controlled blood sugar
• Nausea, vomiting, and feeling of fullness after small meals
• Pale, greasy, or floating stools (steatorrhoea) — indicating fat malabsorption from pancreatic enzyme deficiency
• Fatigue and general weakness
• Blood clots in unusual locations (deep vein thrombosis) — a paraneoplastic manifestation sometimes preceding diagnosis

Painless jaundice in any adult is a red flag that requires same-week imaging and specialist review. Do not wait. Book a consultation with a pancreatic cancer specialist at your nearest CION location.

Why Patients Choose CION for Pancreatic Cancer Treatment in Hyderabad

Sixteen reasons our patients pick CION — across surgical expertise, structured borderline-resectable pathway, targeted therapy, and palliative care.

Pancreatic Cancer Diagnosis at CION

An accurate diagnosis that establishes both the histological type and resectability status is essential before any treatment decision. CION's diagnostic pathway integrates imaging, endoscopy, and molecular testing.

Imaging

• CT Scan (multiphasic, pancreatic protocol) — the gold standard first-line imaging investigation; defines tumour size, location, involvement of major vessels (superior mesenteric artery/vein, portal vein, coeliac axis), and distant spread; determines resectability
• MRI / MRCP — used for biliary anatomy assessment, liver lesion characterisation, and when CT findings are indeterminate
• PET-CT — for staging and detection of distant metastases not visible on CT; used selectively in borderline resectable cases before surgery

Endoscopic Ultrasound (EUS) — The Diagnostic Gold Standard

EUS is the most sensitive imaging modality for small pancreatic tumours and the standard method for obtaining tissue diagnosis. A thin flexible scope with an ultrasound probe is passed through the mouth to the stomach and duodenum, allowing real-time, high-resolution imaging of the pancreas from inside the gastrointestinal tract. EUS-guided fine needle aspiration (FNA) or fine needle biopsy (FNB) obtains tissue for histological confirmation without the risks of percutaneous biopsy. CION's diagnostic pathway includes EUS for all cases where tissue confirmation is required before treatment — a capability that distinguishes CION from centres that rely solely on CT-guided biopsy.

Blood Tests

• CA19-9 tumour marker — elevated in the majority of PDAC cases; used for diagnosis support, treatment response monitoring, and surveillance after surgery
• Liver function tests — assess biliary obstruction severity and fitness for surgery
• Germline genetic testing — for BRCA1/BRCA2, PALB2, and other hereditary mutations; influences systemic therapy eligibility (olaparib for BRCA-mutated advanced PDAC) and guides family screening

Pancreatic Cancer Staging and Resectability

Pancreatic cancer staging is determined by TNM classification, but the clinically critical categorisation is resectability status — which directly determines the treatment pathway. CION's tumour board assesses resectability using the high-quality CT imaging and the criteria outlined below.

All staging and resectability assessments are performed by CION's multidisciplinary tumour board. The categorisation above reflects NCCN criteria and is subject to individual patient factors including performance status, liver function, and comorbidities.

Borderline Resectable Pancreatic Cancer — What It Means and How CION Approaches It

Borderline resectable pancreatic cancer is one of the most important — and most misunderstood — diagnoses in oncology. It refers to tumours that abut (touch) but do not clearly encase major blood vessels such as the superior mesenteric artery (SMA), superior mesenteric vein (SMV), portal vein, or coeliac axis. These tumours cannot be removed with clear surgical margins in their current state — but with the right pre-surgical treatment, they may become resectable.

Most hospital treatment pages in Hyderabad do not address borderline resectable disease — leaving patients who receive this diagnosis without a clear local pathway. CION manages borderline resectable pancreatic cancer through a structured neoadjuvant approach:

1. 1

   Multidisciplinary tumour board review

   Confirm borderline resectable status with high-quality pancreatic protocol CT; assess performance status and fitness for chemotherapy.

2. 2

   Neoadjuvant chemotherapy

   4–6 months of systemic chemotherapy (gemcitabine + nab-paclitaxel or FOLFIRINOX regimen depending on patient fitness) to shrink the tumour and create a margin around blood vessels.

3. 3

   Re-staging imaging

   Repeat CT scan after neoadjuvant therapy to assess response and determine whether the tumour has been downstaged to resectable.

4. 4

   Surgery

   If re-staging confirms adequate response and resectable margins, proceed to Whipple procedure or distal pancreatectomy; vascular resection and reconstruction performed where required.

5. 5

   Post-surgical adjuvant therapy

   Additional chemotherapy following surgery to reduce recurrence risk.

Not all borderline resectable patients will ultimately proceed to surgery — but every borderline resectable patient deserves a structured attempt at curative treatment. If you have been told your pancreatic cancer 'might be operable' or is 'close to the blood vessels,' ask for a second opinion from CION's tumour board before accepting a non-surgical pathway.

Pancreatic Cancer Treatment at CION Cancer Clinics

CION follows NCCN protocol-driven treatment planning for all pancreatic cancer subtypes and stages. Every case is reviewed by a multidisciplinary tumour board before treatment begins.

Surgical Oncology — Pancreatic Cancer Surgery

Surgery is the only potentially curative treatment for pancreatic cancer. CION's surgical oncology team, led by Dr. Paila Gowri Naidu (M.Ch Surgical Oncology, BHU Varanasi) and Dr. Sridhar Kamani (DrNB Surgical Oncology), performs the full range of pancreatic resections.

• Whipple Procedure (Pancreaticoduodenectomy) — the gold standard surgery for cancers in the head of the pancreas. One of the most complex abdominal operations in oncology, involving removal of the head of the pancreas, the duodenum, gallbladder, part of the bile duct, and sometimes part of the stomach. Performed in a dedicated hepatopancreaticobiliary surgical setting with ICU support.
• Distal Pancreatectomy — removal of the body and tail of the pancreas, usually with the spleen, for tumours in these locations. Can be performed open or laparoscopically in carefully selected patients.
• Total Pancreatectomy — removal of the entire pancreas, duodenum, bile duct, gallbladder, and spleen. Indicated for diffuse or multifocal tumours. Requires lifelong insulin therapy and pancreatic enzyme replacement.
• Palliative Surgical Bypass — for patients with advanced disease causing biliary obstruction (jaundice) or gastric outlet obstruction; surgical bypass (hepaticojejunostomy, gastrojejunostomy) relieves obstruction and improves quality of life.

Chemotherapy — Neoadjuvant, Adjuvant, and Palliative

Chemotherapy is used at every stage of pancreatic cancer management. CION's medical oncology team delivers current NCCN preferred regimens in a comfortable day-care setting.

• Neoadjuvant Chemotherapy (before surgery) — for borderline resectable and locally advanced disease; aims to downstage the tumour and improve the chance of achieving clear surgical margins
• Adjuvant Chemotherapy (after surgery) — recommended for all resected pancreatic cancer patients for 6 months post-surgery per NCCN guidelines; significantly reduces recurrence risk
• Palliative Chemotherapy (for advanced/metastatic disease) — improves survival and quality of life; NCCN preferred regimens include gemcitabine + nab-paclitaxel and modified FOLFIRINOX for fit patients
• Targeted Therapy (Olaparib) — PARP inhibitor, NCCN-recommended maintenance therapy for patients with advanced PDAC and germline BRCA1/BRCA2 mutations whose disease has not progressed on platinum-based chemotherapy; CION's genetic counselling service identifies eligible patients

Radiation Therapy

CION's radiation oncology team uses advanced, precisely targeted techniques for pancreatic cancer:

• Chemoradiation (concurrent chemotherapy + radiation) — for locally advanced, unresectable Stage III pancreatic cancer; chemotherapy sensitises cancer cells to radiation, improving local control
• Stereotactic Body Radiation Therapy (SBRT) — high-dose, precisely targeted radiation delivered in a small number of fractions; an option for locally advanced disease not responding to chemotherapy, or for patients not fit for surgery
• IMRT (Intensity-Modulated Radiation Therapy) — used to deliver therapeutic doses to the pancreatic tumour while protecting the duodenum, stomach, kidneys, and spinal cord
• Palliative radiation therapy — for pain control from local tumour invasion or bone metastases

Pancreatic Neuroendocrine Tumour (PNET) Treatment in Hyderabad

PNETs are fundamentally different from PDAC in their biology, behaviour, and treatment — yet most hospital treatment pages in Hyderabad fail to address them. If you have been diagnosed with a PNET rather than pancreatic adenocarcinoma, your prognosis, treatment options, and the specialists you need are different.

• Surgery — the preferred treatment for resectable PNETs of any grade; even metastatic PNETs may benefit from debulking surgery to control hormonal symptoms and prolong survival
• Somatostatin Analogues (octreotide LAR, lanreotide) — for functioning PNETs to control hormonal symptoms and inhibit tumour growth in Grade 1 and Grade 2 tumours
• Everolimus (mTOR inhibitor) — approved for progressive, well-differentiated PNETs; significantly improves progression-free survival
• Sunitinib (TKI) — approved for well-differentiated pancreatic NETs; used for progressive disease
• Peptide Receptor Radionuclide Therapy (PRRT) — for somatostatin receptor-positive PNETs; a specialised treatment coordinated through CION's referral network
• Chemotherapy — for high-grade (Grade 3) poorly differentiated pancreatic NETs, which behave more like PDAC and are treated with platinum-based regimens

Palliative and Supportive Care — Central to Pancreatic Cancer Management

Approximately 80% of pancreatic cancer patients present at Stage III or Stage IV, when curative surgery is not possible. This does not mean that nothing can be done — it means that the goals of care shift to controlling the disease, relieving symptoms, maintaining nutritional status, and preserving quality of life for as long as possible. CION's palliative care approach for pancreatic cancer is a substantive, integrated pathway — not an afterthought:

• Biliary drainage — for patients with obstructive jaundice, endoscopic biliary stenting or surgical bypass relieves jaundice, itching, and liver impairment; improves tolerance of chemotherapy
• Pain management — specialist pain management including coeliac plexus neurolysis (nerve block) for intractable pancreatic pain; a procedure that can provide months of meaningful pain relief
• Pancreatic enzyme replacement therapy (PERT) — vital for maintaining nutritional absorption; pancreatic exocrine insufficiency is near-universal in advanced PDAC
• Nutritional support — dietitian-led guidance to maintain weight and strength during chemotherapy; high-calorie, easily digestible nutrition plans tailored to each patient
• Psychological support — psycho-oncology counselling for patients and families; managing the emotional impact of a pancreatic cancer diagnosis requires dedicated support
• Insulin management — for patients with diabetes arising from pancreatic destruction or total pancreatectomy
• Ascites management — drainage (paracentesis) for patients with advanced disease and symptomatic fluid accumulation

At CION, every Stage III and Stage IV pancreatic cancer patient has a dedicated supportive care plan established alongside their oncology treatment — because managing this disease well means managing the whole patient, not just the tumour.

Multidisciplinary Tumour Board — Every Case Reviewed by a Team

Pancreatic cancer requires one of the most complex multidisciplinary decisions in oncology — particularly for borderline resectable disease, where the choice between immediate surgery and neoadjuvant chemotherapy first can determine whether a patient ever reaches the operating table. At CION, every pancreatic cancer case is reviewed by a tumour board before any treatment decision:

• Resectability assessment using standardised NCCN criteria on high-quality pancreatic protocol CT
• Performance status and liver function evaluation for chemotherapy and surgical fitness
• Germline genetic testing (BRCA/PALB2) discussed for all patients — to assess targeted therapy eligibility
• Neoadjuvant vs upfront surgery decision for borderline resectable cases
• Biliary drainage planning before chemotherapy for jaundiced patients
• PNET vs PDAC pathway differentiation based on histology and grade
• Palliative care plan established from diagnosis for Stage III/IV patients
• Digital coordination across all 7 Hyderabad locations for uninterrupted care

Pancreatic Cancer Treatment Cost in Hyderabad

Pancreatic cancer treatment costs vary significantly based on stage, resectability, and whether surgery, chemotherapy, or palliative care is the primary pathway. The following ranges are based on current Hyderabad market data:

Costs are indicative. A personalised treatment cost estimate is provided following your initial oncology consultation at CION.

Financial Support Options

• Aarogyasri Scheme — cashless treatment coverage for eligible Telangana residents (White Ration Card holders). CION is Aarogyasri empanelled.
• EMI Facility — flexible instalment-based payment options available for all patients.
• Private Health Insurance — CION works with all major TPAs for cashless hospitalisation.

Pancreatic Cancer Care Near You — In Hyderabad & Beyond

CION operates 35+ centres across Telangana and Andhra Pradesh. Find your nearest pancreatic cancer specialist or explore care options in your city.

Pancreatic Cancer Care in Hyderabad — by Location

Pancreatic Cancer Care Beyond Hyderabad

Travelling for treatment? We may have a centre right where you are — across Telangana and Andhra Pradesh.

Not seeing your city? Call 18002028726 — we'll connect you to the nearest CION centre or arrange a teleconsultation.

Get a Free Written Second Opinion from CION's Tumour Board

Our multidisciplinary team reviews your imaging, pathology, and existing treatment plan — before you commit to Whipple surgery or chemotherapy.

Frequently Asked Questions — Pancreatic Cancer Treatment

Common questions about pancreatic cancer treatment in Hyderabad — answered by CION's oncology team.

Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.